Biotech Yanyang Bio, focusing on the research and development of innovative drugs based on human active bacteria, will continue to promote its R&D and commercialization capacity with the fresh proceeds.
Biotech Yanyang Bio (Chinese: 厌氧生物) completed the Series A financing round worth CNY 100 million (USD 14.8 million) recently. The round was led by Dalton Venture (Chinese: 道彤投资) and Chengdu Science & Technology Innovation Investment (Chinese: 成都科创投), with the participation from CDF-Capital (Chinese: 创东方投资) and Zhongxi Capital (Chinese: 中喜基金).
The funds will be used for the talent team building, phase II clinical trials of live bacteriophage drugs, the development of drug candidate pipelines and the construction of a bacteriophage drug manufacturing platform.
Founded in 2019, Yanyang Bio is a high-tech enterprise engaged in the research and development of innovative drugs for human microbiota. The company has mastered the whole chain of core technologies for the research and development of innovative drugs for active bacteria, such as high-throughput screening of anaerobic microorganisms, conservation, evaluation and active bacteria preparation development. It has a human anaerobic microorganism strain library covering many regions in China. Besides, Yanyang Bio has been working in human intestinal and vaginal flora R&D for many years and is a leading company in the field of human microbial innovation drug development in China.
The company's competitors include Zhiyi Biotech (Chinese: 知易生物), MoonBiotech (Chinese: 慕恩生物) and OswkBio (Chinese: 欧赛微科).